Immunicum AB (publ) today released an updated report on safety and survival data from the ongoing phase I/II study with INTUVAX for patients with primary liver cancer. Of a total of seven fully treated patients, four showed a prolonged survival as compared to expected based on historical data. Two of the three patients that are still alive have not yet passed their expected median overall survival.
Read the press release here: Press release 150824 – HCC-update
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805